Overview

(TNX-1500) in Kidney Transplant Recipients

Status:
NOT_YET_RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

Phase:

PHASE2

Details

Lead Sponsor:

Ayman Al Jurdi, MD

Collaborator:

Tonix Pharmaceuticals, Inc.

Treatments:

Kidney Transplantation